OQROGet OQRO Pro
Insider trade

ADMA Biologics, Inc. (ADMA)CEO sold ~$297K

Adam S Grossman, CEO at ADMA Biologics, Inc., sold ~$297K of ADMA Biologics, Inc. shares.

~$297K
Approx. value · 15K sh @ $19.79
2.01M
Holds after · shares reported
Traded
Dec 15, 2025
Filed
Dec 17, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 24, 2025Insider · 1 personInsiders: 2 sales (~$336K)
  2. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results
  3. Nov 19, 2025Insider · 1 personInsiders: 2 sales (~$336K)
  4. Dec 15, 2025 · this disclosureInsiderCEO sold ~$297K of ADMA shares in the open market

What came next

  1. Dec 15, 2025InsiderCEO sold ~$119K of ADMA shares in the open market
  2. Jan 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  3. Feb 17, 2026Insider · 1 personInsiders: 2 sales (~$338K)
  4. Feb 20, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results“On February 20, 2026, Brad Tade notified the Company that he is retiring from his position as Chief Financial Officer and Treasurer of the Company effective at the close of business on February 25, 2026, following the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”).”
  5. Mar 5, 2026Insider · First insider buy since Aug 2023Director purchased ~$110K of ADMA shares in the open market
  6. Mar 6, 2026InsiderDirector purchased ~$108K of ADMA shares in the open market
  7. Mar 9, 2026InsiderOfficer sold ~$158K of ADMA shares in the open market
  8. Mar 16, 2026Insider · 1 personInsiders: 2 sales (~$318K)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for ADMA Biologics, Inc.

For ADMA Biologics, Inc., OQRO holds 4 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ADMA page.

Other recent filings by Adam S Grossman, President and CEO

The full history of Adam S Grossman, President and CEO is on the profile page.

How this filing works

Other disclosures at ADMA Biologics, Inc.

Everything OQRO holds on this company is on its ADMA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data